Content available at: https://www.ipinnovative.com/open-access-journals

IP Journal of Diagnostic Pathology and Oncology

Journal homepage: https://www.jdpo.org/

Review Article

Emerging role of digital pathology and artificial intelligence in cancer diagnosis and prognostication

Khuspe Pankaj Ramdas[1]*, Sitaram Kale[1], Trushali Mandhare[2], Pooja Kashid[2], Dipali Hagir[2], Vinay Gaikwad[3], Dipali Mane[1]

[1]Shriram Shikshan Sanstha's College of Pharmacy, Paniv, Maharashtra, India
[2]Navsahyadri Institute of Pharmacy, Nasrapur, Maharashtra, India
[3]SPM's College of Pharmacy, (Poly), Akluj, Maharashtra, India

Abstract

The field of cancer diagnosis and prognosis is undergoing a revolution thanks to the combination of digital pathology and artificial intelligence (AI). Despite being the gold standard, traditional histological procedures are frequently constrained by subjectivity, inter-observer variability, and the increasing workload of pathologists. Whole-slide imaging (WSI) in digital pathology makes it possible to digitize histology slides, improving pathological data processing, sharing, and storage. These digital images represent a rich source for computational analysis when combined with AI, especially machine learning (ML) and deep learning (DL) algorithms, which help with accurate and repeatable interpretations. Recent developments have shown that AI models can accurately predict patient outcomes, identify cancers, categorize tumor subtypes, and evaluate histological grading. Furthermore, new morphological and molecular biomarkers are being found thanks to AI-enhanced digital pathology, which makes individualized treatment plans easier. Its prognostic potential is further increased by integration with multi-omics data, which makes it possible to forecast treatment outcomes and disease progression. Widespread clinical use is hampered by a number of issues, despite the promise: data consistency, algorithm validation, regulatory compliance, and ethical worries about algorithmic bias and patient data privacy. However, the combination of AI and digital pathology has enormous potential to improve workflow efficiency, increase diagnostic accuracy, and revolutionize oncology patient care. The technological developments, present uses, and potential future developments of digital pathology and artificial intelligence in cancer diagnosis and prognostication are thoroughly covered in this study, which also highlights significant discoveries and persistent difficulties in integrating these advancements into standard clinical practice.

Keywords: Digital pathology, Artificial intelligence, Cancer diagnostics, Prognostication, Machine learning.

Received: 17-03-2025; **Accepted:** 19-04-2025; **Available Online**: 01-05-2025

1. Introduction

As the leading cause of illness and mortality worldwide, cancer continues to be one of the most urgent global health issues. The World Health Organization estimates that cancer killed almost 10 million people in 2020, and that the disease's incidence will continue to climb as a result of aging populations, environmental causes, and shifting lifestyle choices. Effective cancer management still depends on early and precise diagnosis, even with significant advancements in oncology. In addition to increasing the chances of good treatment outcomes, timely detection and accurate prognostication are essential for choosing the best therapeutic approaches and tracking the course of the disease.[1]

In oncology, pathology especially histological evaluation has long been the gold standard for diagnosis. In order to guide clinical decision-making, tissue-based analysis offers crucial insights regarding tumor kind, grade, stage, and biomolecular features. Conventional pathology does have several drawbacks, though. Slide interpretation by hand takes a lot of time and is frequently prone to inter-observer variability, particularly in complex circumstances. Furthermore, healthcare systems are under tremendous strain due to the growing demand for pathology services and the

*Corresponding author: Khuspe Pankaj Ramdas
Email: khuspepankaj@gmail.com

http://doi.org/10.18231/j.jdpo.2025.004

worldwide scarcity of qualified pathologists.[2,3] The diagram 1 shows the global cancer data in the year 2020.[4]

Digital pathology has become a game-changing advancement in diagnostic medicine in recent years. Digital pathology facilitates remote access, simpler data exchange, and integration with computational tools by utilizing whole-slide imaging (WSI) technology to transform glass slides into high-resolution digital images. The foundation for integrating artificial intelligence (AI) into diagnostic processes has been established by the digitization of pathology. Artificial intelligence (AI), in particular machine learning and deep learning algorithms, has proven to be very accurate and quick at analyzing complex histological patterns, quantifying tissue properties, and helping with diagnostic and prognostic tasks. Many of the problems with conventional cancer diagnosis may be resolved by the combination of AI and digital pathology. By automatically analyzing images, highlighting areas of interest, and making diagnostic recommendations, AI-powered technologies can help pathologists work more efficiently and consistently. Furthermore, by recognizing minute morphological traits and connecting them to clinical outcomes, AI has demonstrated promise in prognostication, opening the door for precision oncology **Figure 1**.[5,6]



Figure 1: Global cancer data[4]

The purpose of this review is to examine how AI and digital pathology are developing in relation to cancer diagnosis and prognosis. The limits of conventional diagnostic techniques and the development of digital pathology are covered first. It then explores the fundamentals and uses of AI in histopathological image processing, emphasizing significant developments and practical applications. The review continues by describing future directions and the possible influence of these technologies on cancer care. It also discusses present adoption hurdles, including technological, ethical, and regulatory barriers. The essay aims to highlight the vital role that AI and digital pathology play in developing oncologic diagnoses and enhancing patient outcomes through this thorough review.[7,8]

2. Traditional Methods in Cancer Diagnosis

Traditional pathology methods, especially histopathology and immunohistochemistry (IHC), have long been used to diagnose cancer and are now essential components of clinical oncology. Clinicians can now diagnose cancer kinds, assess tumor grade, and inform treatment choices because to these methods' critical insights into tumor appearance, cellular architecture, and biomarker expression. But the inherent drawbacks of these traditional methods are becoming increasingly apparent as the number and complexity of diagnostic data rise.[9]

2.1. Histopathology and immunohistochemistry: Cornerstones of diagnostic pathology

Hematoxylin and eosin (H&E)-stained tissue samples are examined under a microscope in histopathology, which enables pathologists to see the cytological and structural characteristics that characterize neoplastic processes. For early cancer diagnosis and categorization, it is still the gold standard. By employing antigen-antibody interactions to identify certain proteins in tissue slices, immunohistochemistry concurrently provides a molecular dimension. IHC is essential for tumor subtyping, locating predictive and prognostic biomarkers (such as PD-L1 in lung cancer and HER2 in breast cancer), and distinguishing between morphologically similar cancers. By connecting DNA profiles with histology discoveries, these techniques have made a substantial contribution to the development of tailored therapy. However, the diagnostic procedure is inherently subjective because they rely heavily on the knowledge and judgment of qualified pathologists.[10]

2.2. Limitations of traditional diagnostic techniques

2.2.1. Subjectivity and human error

The dependence on human interpretation, which can introduce a degree of subjectivity, is a significant drawback of conventional pathology. Years of expertise are necessary for the visual evaluation of tissue slides, and even among highly skilled pathologists, differences in interpretation might arise. Diagnostic variability may be caused by elements including weariness, differing exercise levels, and minute variations in tissue presentation. Inaccurate or delayed diagnosis due to misinterpretation may have an impact on treatment plans and patient outcomes.[11,12]

2.2.2. Time-consuming workflow

From specimen collection, fixation, embedding, sectioning, and staining to slide preparation and microscopic examination, the diagnostic procedure utilizing histopathology and IHC entails a number of manual and sequential procedures. The turnaround times for diagnosis are prolonged by the meticulous attention to detail and quality control required at each stage. These manual operations can cause backlogs in hectic clinical settings with growing caseloads, which can postpone the start of vital cancer treatments. Diagnostic delays are further increased by repeat testing because of poor sample quality or staining artifacts.[13]

2.2.3. Limited reproducibility and Inter-observer variability

Traditional pathology still has serious concerns about reproducibility. When analyzing the same tissue slide, various pathologists may reach different results, particularly in situations that are difficult or borderline. When grading tumors, evaluating mitotic activity, or interpreting ambiguous IHC staining results, inter-observer variability is very noticeable. These discrepancies have the potential to erode trust in diagnosis, especially when multicenter clinical trials or the use of standardized treatment regimens are involved. Furthermore, the incorporation of conventional techniques into automated or high-throughput diagnostic systems is impeded by repeatability issues.[14] The need for diagnostic instruments that offer reliable, unbiased, and data-rich results has increased as precision medicine emerges as a key paradigm in oncology. While without undermining its significance, classical pathology's shortcomings draw attention to the need for supplementary technologies that can improve diagnostic precision and lower variability. Artificial intelligence and digital pathology are becoming revolutionary approaches to these problems, providing high-throughput, scalable, and repeatable substitutes for traditional techniques. Although histology and immunohistochemistry are still essential for diagnosing cancer, their shortcomings call for the use of cutting-edge technology. In the age of personalized healthcare, new digital techniques are positioned to supplement traditional pathology by tackling problems of subjectivity, workflow inefficiencies, and repeatability. This will guarantee more accurate and timely cancer diagnoses.[15]

3. The Rise of Digital Pathology

The term "digital pathology" describes the use of sophisticated imaging technology and software systems to digitize and analyze histology slides computationally. It converts conventional microscopy-based techniques into image-based, data-rich workflows that improve pathology data presentation, interpretation, and sharing. Whole-slide imaging (WSI), a method that makes it possible to scan entire glass slides at high resolution in order to create thorough digital copies, is a fundamental part of digital pathology. Pathologists may analyze tissues on digital platforms with precision on par with or even better than light microscopy thanks to these whole-slide images, which preserve all the minute histological details needed for an appropriate diagnosis.

Standard slide preparation, which includes fixation, embedding, sectioning, and staining, is the first step in digitizing tissue samples. High-throughput slide scanners are then used to scan these slides and produce high-resolution images. Features like annotation, zooming, side-by-side comparisons, and integration with artificial intelligence (AI) tools are made possible by the digital pathology software that manages and stores the resultant digital slides in image databases.[17,18] The comparative overview of traditional pathology vs. digital pathology with AI integration in the **Table 1**.[16]

3.1. Advantages of digital pathology

The ability of digital pathology to lessen subjectivity in histopathological interpretation is among its most important advantages. Digital pathology reduces inter-observer variability, a common drawback in traditional pathology, by digital standardization and algorithm-assisted quantification. For instance, AI systems can detect and quantify histologic features such as nuclear atypia, mitotic figures, and tissue architecture with surprising consistency, boosting the diagnostic precision and reproducibility of cancer evaluations. Digital pathology offers remote consultations and telepathology, breaking down geographical obstacles to diagnostic competence.[8] Pathologists can provide diagnostic services in areas with limited pathology resources, collaborate internationally, and get second views by facilitating the transmission and sharing of digital slides over secure systems. This is particularly important in oncology since prompt and precise diagnosis has a direct impact on treatment choices. Furthermore, by eliminating the logistical limitations of physical slide transfer, telepathology enables specialized consultations, improving patient care quality and turnaround times.[19]

Table 1: Comparative overview of traditional pathology vs. Digital pathology with AI integration[12,13,14,15,16]

Aspect	Traditional Pathology	Digital Pathology with AI
Data Format	Glass slides	Whole-slide digital images (WSI)
Accessibility	Local, physical access required	Remote, real-time access
Analysis	Manual, observer-dependent	Automated, AI-assisted interpretation
Diagnostic Accuracy	Variable, subjective	High, consistent with validated algorithms
Efficiency	Time-consuming	High-throughput and time-efficient
Archiving	Physical storage (space-consuming)	Cloud or server-based digital storage
Collaboration	Limited, delayed consultations	Real-time global sharing and consultation
Scalability	Limited by human workload	Scalable with automated systems

Electronic health records (EHRs), laboratory information systems (LIS), radiology platforms, and other larger healthcare technology can all be seamlessly integrated with digital pathology. This interoperability facilitates multidisciplinary decision-making and improves the diagnostic workflow. A more thorough understanding of the patient's condition can be obtained, for example, by seeing a digital slide in conjunction with a genetic profile or radiologic imaging. Additionally, AI models can be trained using digital pathology data in combination with imaging and genomic information, propelling advancements in customized medicine and integrated diagnostics.[20]

3.2. Current applications of digital pathology in oncology

The tumor characterization, including cancer grading, staging, and subtyping, digital pathology is essential. Certain histological characteristics, such as glandular differentiation, necrosis, and stromal response, can be detected by AI-powered technologies and are crucial for precise grading. These methods provide quantitative indicators that can be harmonized across institutions in addition to enhancing uniformity among pathologists. Since grading systems for colon, breast, and prostate cancers mostly depend on morphological details, digital analysis is very helpful in these cases. A key component of contemporary oncology, the detection and quantification of molecular markers are much improved by digital pathology. Precision assessment of biomarker expression levels, including HER2, PD-L1, Ki-67, and EGFR, is made possible by integration with immunohistochemistry (IHC) and in situ hybridization (ISH). Staining intensity and the proportion of positive cells can be objectively scored by sophisticated image processing algorithms, which lowers observer-dependent variability and increases the precision of biomarker-driven treatment choices. Additionally, routine H&E-stained images can now be used to forecast molecular changes thanks to AI-based algorithms, creating new opportunities for non-invasive molecular diagnostics.[21,22]

Integrating digital pathology with EHRs, which offers a centralized, longitudinal view of patient data, is another crucial use. A comprehensive picture of disease is made possible by connecting pathology images with clinical history, radiologic data, treatment plans, and genomic profiles. Clinicians may predict the course of a disease and adjust therapeutic approaches accordingly thanks to this integration, which also allows predictive modeling and decision assistance tools. The construction of AI models that link histological characteristics to outcomes is made easier for researchers by this standardized data environment, which enhances the prognostic value of digital pathology. A key component of precision oncology is quickly becoming digital pathology. It has the potential to revolutionize cancer diagnosis and prognostication by improving diagnostic accuracy, facilitating international collaboration, and integrating with other clinical systems. Digital pathology will continue to develop from a diagnostic tool to a fully integrated platform propelling innovation in cancer care as digital infrastructure ages and AI algorithms advance.[23,24]

4. Artificial Intelligence in Cancer Diagnosis

In oncology, artificial intelligence (AI) has become a game-changer, especially when it comes to improving the precision and effectiveness of cancer diagnosis. Fundamentally, artificial intelligence (AI) refers to computer programs created to learn, reason, and self-correct in order to simulate human intelligence. Machine learning (ML) is a subset of artificial intelligence (AI) that allows algorithms to learn from massive datasets and gradually get better at what they do without having to be explicitly programmed for every situation.[25]

Table 2: Applications of artificial intelligence in cancer diagnosis & prognostication[35]

AI Application	Function	Clinical Impact
Tumor Detection	Identifies cancerous regions in histopathological slides	Enhances early detection and screening accuracy
Tumor Classification	Differentiates between cancer subtypes	Guides appropriate treatment selection
Grading and Staging	Evaluates morphological features for cancer grading	Improves staging accuracy and risk stratification
Prognostic Modeling	Predicts patient outcomes and disease progression	Supports personalized therapy decisions
Biomarker Discovery	Identifies morphological and molecular markers	Facilitates targeted therapies and precision medicine
Workflow Optimization	Prioritizes cases and flags anomalies	Reduces workload and improves turnaround time

In cancer diagnosis, ML algorithms are trained on enormous quantities of pathological and clinical data to discover complicated patterns that may defy human observers. In order to obtain more complex insights, this entails combining genetic, proteomic, and clinical data in addition to examining histopathological images. More precise and early cancer detection has been made possible by machine learning's capacity to identify minute morphological changes and link them with disease characteristics, greatly improving patient outcomes.[26]

4.1. Types of AI techniques in digital pathology

4.1.1. Image recognition and pattern analysis

A key use of AI in digital pathology is image recognition, which interprets digital histopathology slides to find regions of interest, like cancerous cells or aberrant tissue structures. In order to grade and classify tumors, pattern analysis algorithms are made to identify morphological characteristics linked to cancer, such as nuclear atypia, mitotic figures, and architectural abnormalities. These methods lessen inter-observer variability among pathologists by enabling standardized assessments. In order to provide extra prognostic value, sophisticated image recognition models can even quantify histological features such as necrotic areas or tumor-infiltrating cells.[27]

4.1.2. Deep learning and convolutional neural networks (CNNs)

Multi-layered artificial neural networks are used in deep learning, a specific area of machine learning, to represent high-level abstractions in data. Convolutional Neural Networks (CNNs) are among the most successful designs in medical image processing. Because of their capacity to learn spatial hierarchies of information, CNNs are especially well-suited for visual data.[28] CNNs eliminate the need for manual feature engineering by automatically extracting features from raw histopathology images. These networks have shown remarkable performance in the diagnosis of cancer, reaching accuracy levels on some tasks that are on par with or even higher than those of experienced pathologists. CNNs are frequently used to partition tissue compartments with exceptional precision, grade malignancy, and discover tumor margins.[29]

4.1.3. Natural language processing (NLP) for diagnostic reports

Natural Language Processing (NLP) is another strong AI method used to extract structured information from unstructured clinical writings, such as pathology reports and electronic health records (EHRs). NLP algorithms can discover essential diagnostic phrases, measure sentiment and certainty, and link findings with pertinent clinical codes. NLP helps correlate imaging and histological results with patient demographics, medical history, and response to treatment in cancer diagnostics. By effectively mining historical data, it also makes large-scale retrospective research possible, which aids in ongoing learning and model improvement.[30]

4.2. AI-Driven platforms in cancer diagnosis

4.2.1. Automated image analysis for tissue classification

Tissue samples can be automatically classified as benign, pre-malignant, or malignant using AI-powered platforms. These techniques locate pathological characteristics including carcinoma in situ, invasive cancers, or dysplastic alterations by scanning whole-slide images (WSIs) using pre-trained models. Automated analysis guarantees uniformity and reproducibility while also speeding up the diagnostic process. To help pathologists make accurate diagnoses, AI systems, for example, can distinguish between ductal and lobular breast carcinomas or identify subtypes of lung cancer based on histomorphological patterns.[31,32]

4.2.2. Detection of tumor heterogeneity

The existence of many cell populations within a single tumor is known as tumor heterogeneity, and it can affect how the disease progresses and how well a treatment works. This intra-tumoral complexity may be missed by conventional microscopy, but AI models are able to quantitatively evaluate heterogeneity at the molecular and cellular levels. AI technologies assist in identifying clinically meaningful heterogeneity by examining characteristics including nuclear pleomorphism, stromal composition, and immune cell spatial distribution. In order to stratify patients for individualized treatments and track the progression of the disease over time, this information can be extremely important.[33]

4.2.3. Predictive modeling for cancer detection

Based on clinical and image-derived data, AI-driven predictive models are being utilized more and more to determine the probability of malignancy in worrisome lesions. To find cancer precursors or early-stage tumors that could otherwise go undetected, these algorithms are trained using labeled datasets. To present a comprehensive picture of tumor biology, predictive algorithms can combine pathology and imaging data. For instance, the sensitivity and specificity of cancer screening instruments, like those employed in lung and breast cancer programs, can be improved by combining radiomics-based models with histological insights.[34] The applications of artificial intelligence in cancer diagnosis & prognostication are enlisted in **Table 2**.[35]

5. Case Studies and Examples of AI in Cancer Diagnosis

5.1. Breast cancer

Breast cancer is one of the most researched topics for AI applications. On histopathology slides and mammograms, deep learning algorithms have proven adept at spotting cancerous lesions. One prominent example is the AI model developed by Google Health, which demonstrated better accuracy than radiologists in identifying breast cancer from mammograms. Similarly, when it comes to classifying breast cancer and determining receptor status, AI systems such as Paige and Path AI have demonstrated excellent agreement with pathologists.[36]

5.2. Prostate cancer

AI has played a key role in the automated identification of cancer foci in core biopsy samples related to prostate cancer. Prostate adenocarcinomas can be graded using Gleason scoring systems by tools like Paige Prostate and PathAI's prostate models, with performance metrics that correspond to those of skilled uropathologists. In high-throughput screening settings, where manually evaluating each core is laborious and prone to errors, these techniques are especially helpful.[37,38]

5.3. Lung cancer

AI is also important in the diagnosis of lung cancer, particularly in differentiating between squamous cell carcinoma and adenocarcinoma, two subtypes with different treatment options. To lessen the need for costly molecular testing, deep learning models trained on WSIs have been used to predict mutation status (e.g., EGFR, KRAS) directly from tissue shape. Additionally, the early identification of lung nodules and the evaluation of tumor aggressiveness have been enhanced by the combination of AI and radiomics.[39]

6. Success Stories and Clinical Trials

To assess the effectiveness and clinical integration of AI technologies in pathology, several clinical trials are now in progress. AI-assisted diagnosis dramatically decreased diagnostic mistakes in melanoma, according to the US MPath study.[40] AI tools have been successfully incorporated into standard pathology operations at organizations like the University of Pittsburgh Medical Center and the Memorial Sloan Kettering Cancer Center. Better diagnostic turnaround times, less workload, and increased diagnostic confidence are reported by these early adopters. AI has demonstrated enormous promise to complement human abilities in cancer diagnosis and, in many cases, surpass them. By employing complex models such as CNNs and NLP, combined with integrative data analytics, AI is opening the path for faster, more accurate, and more personalized cancer detection. These technologies' place in standard oncology practice is set to become necessary as they develop further and are rigorously validated.[41,42]

The prediction of disease outcomes, including survival, recurrence, and response to treatment, is known as cancer prognostication. It is essential to both individualized care planning and clinical decision-making. Prognostication has historically depended on established variables such as tumor grade and stage, which reveal information about the cancer's aggressiveness and extent of metastasis. While staging techniques like TNM (Tumor-Node-Metastasis) examine the physical extent of the disease, histological grading assesses the degree of differentiation of cancer cells. Furthermore, genetic alterations have a significant impact on prognosis. The biological behavior of cancers and patient outcomes are greatly impacted by mutations in genes such as TP53, KRAS, EGFR, and BRCA1/2. For instance, EGFR mutations in lung cancer direct the use of targeted medicines, while BRCA1/2 mutations in breast and ovarian malignancies are linked to a higher propensity for recurrence and therapeutic resistance. Biomarker expression (e.g., HER2, Ki-67, PD-L1), patient comorbidities, immunological status, and performance status are additional predictive variables. Even while these characteristics are useful, it is still difficult to incorporate them into thorough, personalized prognostic evaluations. Artificial intelligence (AI) provides a clear advantage in this situation by making it possible to analyze intricate, high-dimensional datasets and produce precise, repeatable predictions.[43,44]

Through the integration and analysis of vast amounts of heterogeneous data, artificial intelligence (AI) has become a potent tool for enhancing prognostic models. Compared to traditional statistical models, machine learning (ML) and deep learning (DL) algorithms are more accurate at predicting overall survival (OS) and disease-free survival (DFS) in survival prediction. AI systems are able to identify patterns that traditional methods frequently overlook, such as non-linear correlations between clinical, pathological, imaging, and genetic factors. For instance, AI models trained on multimodal data have demonstrated superior predictive accuracy in glioblastoma and non-small cell lung cancer (NSCLC), allowing for improved patient classification. AI has demonstrated exceptional promise in predicting cancer recurrence in addition to survival. AI algorithms trained on post-operative data, histopathological slides, and radiological scans have shown promise in identifying patients at high risk for relapse. Post-treatment recurrence is a significant clinical challenge. Convolutional neural networks (CNNs) are used to scan tissue pictures and identify microscopic characteristics linked to recurrence risk in breast cancer. Similar to this, early detection of aggressive disease variations has been made easier by recurrence prediction models for colorectal and prostate cancers.[45,46]

AI is changing how doctors predict how patients will react to treatment. AI is capable of predicting whether a patient would benefit from a certain treatment plan by evaluating a mix of genetic, radiological, and histological data. To evaluate the likelihood of a treatment response, for example, AI models have been built to combine immune infiltration patterns, tumor mutational burden, and PD-L1 expression in immunotherapy. AI-powered prediction techniques can evaluate resistance pathways in chemotherapy and help select substitute medicines. These predicted insights minimize needless toxicity and financial strain in addition to optimizing therapeutic approaches.[47]

Integrating genomic data is one of the most exciting new areas in AI-driven cancer prognostication. High-throughput sequencing methods have led to the creation of enormous genomic datasets, many of which are too complicated for traditional analysis. By finding significant patterns in this data that are associated with prognosis, AI fills this gap. Machine learning algorithms are skilled in identifying gene expression profiles, mutation signatures, and epigenetic changes that affect the course of cancer. The use of AI to detect BRCA1 and BRCA2 mutations in ovarian and breast malignancies is a well-known example.[48] These alterations have a substantial impact on long-term results in addition to increasing the risk of cancer. Computational pathology, also known as image-omics, is the term for the ability of AI models to parse genomic sequences in order to quickly and effectively discover these mutations, and occasionally even forecast their occurrence based solely on histological or radiomic traits. In order to provide a more complete view of tumor biology, AI makes it easier to integrate multi-omics data, such as transcriptomics, proteomics, and metabolomics. Refined patient stratification according to molecular subtypes and related hazards is made possible by this integration. In hematologic malignancies and aggressive solid tumors, AI-enabled genomic interpretation has identified novel prognostic biomarkers and resistance networks, paving the door for tailored therapies.[49]

Strong risk assessment tools that support clinical decision-making have also been developed as a result of AI. To help guide treatment intensity, surveillance intervals, and lifestyle changes, these tools assess a variety of factors and calculate individual risk ratings. For example, testing such as Oncotype DX and MammaPrint can determine whether chemotherapy is necessary in cases of early-stage breast cancer. For improved prognosis accuracy, AI-based systems are increasingly expanding on these models by adding other data layers, such as digital pathology features and imaging biomarkers. Gleason grading from digital biopsy slides has been automated and standardized in prostate cancer using AI tools, which has improved diagnostic consistency and decreased inter-observer variability. Similar to this, AI risk tools for hematological malignancies use clinical and cytogenetic data to forecast the likelihood of recurrence following chemotherapy or transplantation. These AI-powered solutions guarantee speed and consistency in clinical workflows in addition to promoting evidence-based decision-making.[50]

The development of individualized, AI-enabled models that dynamically adjust to a patient's changing clinical status is key to the future of cancer prognostication. As longitudinal health data—including follow-up imaging, laboratory results, and real-time physiological data from wearable devices—become increasingly available, AI may constantly refine prognosis based on updated inputs. Therapy and monitoring techniques can be promptly modified thanks to this adaptive learning. The combination of artificial intelligence (AI) with digital twins, which are virtual depictions of a patient's biological state, presents intriguing opportunities for modeling the course of a disease and the results of treatment. With the ability to test various scenarios in silico before putting them into practice in real life, this might completely transform personalized treatment planning.[51]

AI models can be trained across multi-institutional datasets without jeopardizing patient confidentiality thanks to advancements in federated learning and privacy-preserving algorithms, which will increase generalizability and lessen bias. The norms of oncology care are about to be redefined by the application of AI in cancer prognostication. By providing precise survival prediction, recurrence risk estimate, and treatment response forecasting, AI helps doctors to give genuinely tailored, data-driven therapies. AI will continue to develop as a key component of precision oncology in the future as scientific discoveries and technical obstacles are overcome.[52]

7. Challenges in Implementing Digital Pathology and AI

7.1. Technical challenges

7.1.1. Data storage and management (Big Data Issues)

Particularly with whole-slide imaging (WSI), where a single image might be hundreds of megabytes or even terabytes in size, digital pathology produces incredibly enormous datasets. It need a strong infrastructure, such as scalable cloud-based solutions, high-throughput data pipelines, and sophisticated data compression techniques, to manage, store, and retrieve such enormous volumes of high-resolution image data. Low-latency access, long-term archiving, and smooth connection with other hospital information systems are further requirements for effective data management systems. Adoption of digital pathology is frequently severely hampered by inadequate infrastructure in environments with limited resources.[53]

7.1.2. Standardization of imaging protocols

The standardization of imaging and data collecting techniques is another significant obstacle. The dependability of AI-based diagnostic algorithms may be jeopardized by discrepancies in picture formats, staining methods, slide preparation, and scanner resolution. To ensure interoperability between institutions and improve the generalizability of AI models, it is imperative to establish universal standards for metadata annotation, file formats (such as DICOM for pathology), and slide digitalization.[54]

7.1.3. Quality control and validation of AI models

Thorough quality control and validation are essential for the clinical dependability of AI-driven diagnostic systems. AI systems that have been trained on short or skewed datasets frequently perform poorly in a variety of clinical settings and demographics. To guarantee robustness and reduce erroneous predictions, external validation is crucial for multi-center datasets, particularly those with diverse demographics and illness presentations. Furthermore, as clinical data changes over time, ongoing performance monitoring and recalibration are required. A crucial technological requirement is maintaining the repeatability, interpretability, and transparency of AI results.[55]

7.2. Ethical concerns

7.2.1. Data privacy and security

Pathology's digital transition raises important questions regarding cybersecurity and patient data protection. Sensitive patient health data transfer and digitization raises the possibility of data breaches, illegal access, and possible abuse. It is crucial to make sure that data protection laws like the General Data Protection Regulation (GDPR) in the European Union and the Health Insurance Portability and Accountability Act (HIPAA) in the United States are followed. To protect patient confidentiality throughout the data lifecycle, strong encryption techniques, safe cloud environments, and stringent access control procedures must be used.[56]

7.2.2. Bias in AI algorithms and its impact on diagnosis

The caliber and variety of the data used to train AI models are crucial factors. The resulting algorithms may generate biased predictions that negatively impact underrepresented groups if the training data mostly represent particular demographics or illness subtypes. Disparities in diagnosis accuracy, incorrect classification, and even unsuitable treatment recommendations might result from these biases. Curating inclusive datasets, applying fairness-aware machine learning approaches, and regularly auditing algorithms for bias across many demographic and clinical characteristics are all necessary to address this issue.[57,58]

7.3. Regulatory hurdles

7.3.1. FDA and EMA approval processes for AI-driven diagnostic tools

It is difficult and constantly changing to navigate the regulatory environment for AI-based medical devices. Regulatory agencies like the U.S. To prove safety, effectiveness, and clinical utility, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) demand copious documentation. AI systems are dynamic and flexible, which presents a special difficulty, particularly when algorithms change their parameters in response to fresh data. The iterative development of AI models is sometimes difficult for traditional approval frameworks to handle, which calls for new regulatory paradigms like the FDA's Software as a Medical Device (SaMD) approach.[59]

7.3.2. Standards and guidelines for digital pathology in clinical settings

Even though digital pathology is becoming more popular, regional differences in codified standards and practice guidelines still exist. Establishing precise standards for slide digitalization, image quality evaluation, and AI model performance metrics requires cooperation between regulatory bodies and professional associations. Another obstacle to integration and scaling is the absence of defined clinical workflows that use digital pathology tools. Broader clinical acceptance can be facilitated by establishing accrediting schemes and encouraging adherence to guidelines.[60,61]

7.3.3. Integration with existing healthcare systems

AI and digital pathology tools must be seamlessly integrated into current healthcare infrastructures in order to be implemented successfully. Many hospitals continue to use antiquated technologies that aren't built to meet the requirements of AI-based analytics or high-resolution image processing. For efficient workflows and maximum clinical utility, interoperability between pathology image management systems, laboratory information systems (LIS), electronic health records (EHRs), and AI platforms is crucial. In addition to technical advancements, cross-disciplinary cooperation, strategic planning, and a significant financial commitment are needed to achieve this integration.[62]

Healthcare workers' reluctance to the shift to digital workflows may stem from their lack of experience with new technology, worries about losing their jobs, and the learning curve involved in implementing AI solutions. Comprehensive training programs, continuing technical assistance, and the development of a cooperative atmosphere where pathologists, data scientists, and physicians can all work together to validate and implement these systems are all necessary to address these problems. AI and digital pathology have the potential to revolutionize cancer diagnosis and prognosis, but their effective incorporation into clinical practice will depend on resolving a number of significant obstacles. To ensure the safe, efficient, and equitable deployment of these cutting-edge technologies, it is imperative to address technical constraints, ethical issues, regulatory ambiguity, and system-level integration challenges.[63]

8. Future Directions in Digital Pathology and AI

Artificial intelligence (AI) and digital pathology together have the potential to drastically change cancer treatment. New developments in these technologies are improving diagnostic precision, aiding in decision-making, and opening the door to more individualized treatment plans. From real-time diagnostic support to the development of state-of-the-art models that replicate human biology for more accurate therapeutic development, the future of digital pathology and AI promises to further transform oncology. The fascinating advancements and promise of these technologies are examined in this section.[64]

8.1. Advancements in AI algorithms (e.g., explainable AI)

The development of explainable AI (XAI) is one of the most noteworthy future directions in the integration of AI with digital pathology. Although deep learning algorithms in particular have shown impressive diagnostic powers, their "black-box" nature—the inability to explain how conclusions are drawn—has sparked questions about its reliability and potential for therapeutic use. Explainable AI seeks to solve this by increasing the transparency of AI systems' decision-making process. XAI will help pathologists and clinicians better comprehend the rationale behind a given diagnosis or recommended course of treatment in the context of cancer diagnosis. Building clinician trust and ensuring that AI-driven judgments are in line with clinical competence depend heavily on this transparency. Explainable AI could improve clinical decision-making overall and facilitate easier integration into standard pathology workflows by giving AI systems not just a diagnosis but also a concise justification for the results.[65,66]

8.2. Enhancing interoperability with electronic health records and clinical systems

Another exciting direction for future research is the integration of AI-driven digital pathology systems with current clinical and electronic health record (EHR) systems. At the moment, digital pathology functions rather independently of other medical technology. However, the requirement to guarantee smooth interoperability is growing as healthcare depends more and more on interconnected systems. Clinicians can access comprehensive pathology images, a patient's entire medical history, genetic information, and past diagnostic results on a single platform by integrating AI techniques in pathology with EHR systems. More accurate and individualized care will be possible because to this integrated approach, which will improve decision-making, lower errors, and give a complete picture of the patient. Additionally, a collaborative environment where AI supports physicians throughout the diagnostic and treatment planning processes will be fostered by the integration of digital pathology systems with other clinical decision support technologies.[67]

8.3. AI in real-time diagnosis and decision-making support

Real-time diagnostic help is the next big thing in AI and digital pathology. AI algorithms could help doctors make choices in real time while examining patients because of their capacity to handle enormous volumes of data in a matter of seconds. Artificial intelligence (AI) can, for example, rapidly evaluate tissue samples or live images during surgery, giving surgeons and pathologists instantaneous input regarding the presence of malignancy, tumor boundaries, or involvement of lymph nodes. In terms of enhancing surgical results and lowering the possibility of partial tumor resections, this might be revolutionary. AI can also help with real-time prognostication, evaluating the aggressiveness of tumors or forecasting possible metastases based on real-time data. AI can help physicians make quick, data-driven decisions that enhance patient outcomes by providing them with timely insights, especially in high-stakes scenarios like urgent diagnoses or cancer procedures.[68,69]

8.4. Expanding the scope of AI and digital pathology in personalized cancer therapy

AI has the potential to significantly contribute to the rapid rise of personalized medicine as the gold standard of care in oncology. By evaluating a patient's unique cancer profile, digital pathology and AI can help create more individualized therapy regimens. Together with genetic information, AI systems may examine histopathology images to find distinctive tumor features like particular mutations, protein expressions, or metabolic pathways. Based on the genetic composition of the malignancy, these insights allow for the tailoring of medicines, guaranteeing that patients receive the best possible care. The creation of precision oncology medications is aided by AI's capacity to analyze complex data and identify new therapeutic targets. AI and digital pathology will become essential tools for developing more effective and less hazardous customized cancer treatments as they continue to evolve.[70]

8.5. Emerging technologies: AI-powered virtual biopsy and organ-on-a-chip models

AI and digital pathology are becoming ever more powerful thanks to new technology. One exciting advancement is the idea of virtual biopsies driven by AI. These virtual biopsies create a non-invasive tumor diagnosis by combining AI algorithms with imaging technologies including digital pathology slides, CT scans, and MRIs. By lowering the risks and discomforts related to tissue collection, this method may eventually replace conventional biopsies. Additionally, by integrating machine learning models that examine not only tissue properties but also genetic and molecular data, artificial intelligence (AI) can improve the forecasting ability of virtual biopsies and provide a comprehensive picture of the tumor. The creation of organ-on-a-chip models, which replicate human organ systems at the tiny level, is another fascinating innovation. These models can be combined with AI to evaluate treatment responses and cancer progression in a more individualized, controlled setting. Without the need for hazardous clinical trials or animal testing, these in vitro systems might be utilized to test different cancer treatments on patient-specific models, assisting in the identification of the most successful treatment. When combined with AI analysis, these models have the potential to revolutionize the drug discovery process and result in more effective targeted cancer treatment development.[71]

8.6. Global adoption and the potential impact on healthcare systems

Healthcare systems could be significantly impacted by the global use of AI and digital pathology technologies as they develop. AI-driven diagnostic technologies may provide a solution in resource-constrained environments where access to skilled pathologists may be restricted by offering economical and effective substitutes for conventional pathology services. Additionally, because digital pathology systems are scalable, they may be implemented in a variety of healthcare environments, from rural clinics to urban hospitals, guaranteeing more equitable access to high-quality cancer detection. As these technologies develop further, they may play a crucial role in the global healthcare system, increasing patient outcomes, cutting costs, and boosting diagnostic precision. AI and digital pathology have a very bright future ahead of them, with the potential to revolutionize oncology overall and enhance cancer diagnosis and therapy. Cancer care will probably improve significantly as a result of developments in AI algorithms, increased interoperability, real-time decision support, personalized therapies, emerging technologies like virtual biopsies, and the global expansion of these tools. These developments will give clinicians the means to make more accurate, timely, and well-informed decisions.[69,72,73]

9. Conclusion

Oncology is undergoing a paradigm shift with the use of artificial intelligence (AI) and digital pathology in cancer diagnosis and prognostication. The developments in digital pathology have been emphasized in this review, especially with regard to the use of whole-slide imaging (WSI), which makes it easier to digitize and remotely analyze histological data. Combining these technologies with AI algorithms—particularly machine learning and deep learning—improves prognostication, tumor characterisation, and diagnostic accuracy. AI makes it possible to identify new biomarkers and support individualized treatment plans by analyzing large datasets, such as imaging, genetic, and clinical data. A future where cancer is diagnosed more quickly, accurately, and according to the unique characteristics of each patient, with better results and more effective treatment choices, is promised by the combination of digital pathology and artificial intelligence. Pathologists, oncologists, and data scientists must work together in a multidisciplinary manner to successfully deploy these tools. Oncologists offer treatment insights, pathologists offer crucial clinical experience, and data scientists make sure that reliable AI models are developed. To overcome obstacles pertaining to algorithm validation, data standardization, and ethical considerations, such cooperation is essential. The combination of digital pathology and AI has the potential to completely transform cancer treatment, despite some obstacles including obtaining regulatory permission and resolving biases in AI systems. Future patient outcomes and more effective cancer therapies are anticipated as a result of its potential to improve early detection, increase prognostic accuracy, and ultimately tailor treatment.

10. Sources of Funding

None.

11. Conflict of Interest

None.

References

1. Bray F, LaversanneM, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71(3):209-49.
2. Tseng LJ, Matsuyama A, MacDonald-Dickinson V. Histology: The gold standard for diagnosis?. *Can Vet J*. 2023;64(4):389-91.
3. Leong AS, Zhuang Z. The changing role of pathology in breast cancer diagnosis and treatment. *Pathobiology*. 2011;78(2):99-114.
4. Key Cancer Data and Key Figures on IARC: 2020–2021. https://www.iarc.who.int/wp-content/uploads/2021/12/br2021-img-1.jpg
5. Kiran N, Sapna F, Kiran F, Kumar D, Raja F, Shiwlani S, et al. Digital Pathology: Transforming Diagnosis in the Digital Age. *Cureus*. 2023;15(9):e44620.
6. Fatima G, Alhmadi H, Ali Mahdi A, Hadi N, Fedacko J, Magomedova A et al. Transforming Diagnostics: A Comprehensive Review of Advances in Digital Pathology. *Cureus*. 2024;16(10):e71890.
7. Chen S, Ding P, Guo H, Meng L, Zhao Q, Li C. Applications of artificial intelligence in digital pathology for gastric cancer. *Front Oncol*. 2024;14:1437252.
8. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. *Nat Rev Clin Oncol*. 2019;16(11):703–15.
9. Kim SW, Roh J, Park CS. Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips. *J Pathol Transl Med*. 2016;50(6):411–8.
10. He L, Long LR, Antani S, Thoma GR. Histology image analysis for carcinoma detection and grading. *Comput Methods Programs Biomed*. 2012;107(3):538-56.
11. Moscalu M, Moscalu R, Dascălu CG, Ţarcă V, Cojocaru E, Mădălina Costin I, et al. Histopathological Images Analysis and Predictive Modeling Implemented in Digital Pathology-Current Affairs and Perspectives. *Diagnostics (Basel)*. 2023;13(14):2379.
12. Gurcan MN, Boucheron LE, Can A, Madabhushi A, Rajpoot NM, Yener B. Histopathological image analysis: a review. *IEEE Rev Biomed Eng*. 2009;2:147-71.
13. Gurina TS, Simms L. Histology, Staining. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557663/
14. Kamal M. Cervical Pre-cancers: Biopsy and Immunohistochemistry. *Cytojournal*. 2022;19:38.
15. Singla P, Musyuni P, Aggarwal G, Singh H. Precision Medicine: An Emerging Paradigm for Improved Diagnosis and Safe Therapy in Pediatric Oncology. *Cureus*. 2021;13(7):e16489.
16. Go H. Digital Pathology and Artificial Intelligence Applications in Pathology. *Brain Tumor Res Treat*. 2022;10(2):76–82.
17. Aeffner F, Adissu HA, Boyle MC, Cardiff RD, Hagendorn E, Hoenerhoff MJ, et al. Digital Microscopy, Image Analysis, and Virtual Slide Repository. *ILAR J*. 2018;59(1):66–79.
18. Dexter A, Tsikritsis D, Belsey NA, Thomas SA, Venton J, Bunch J, et al. Next Generation Digital Pathology: Emerging Trends and Measurement Challenges for Molecular Pathology. *J Mol Pathol*. 2022;3(3):168–81.

19. Ahmad, Z., Rahim, S., Zubair, M. et al. Artificial intelligence (AI) in medicine, current applications and future role with special emphasis on its potential and promise in pathology: present and future impact, obstacles including costs and acceptance among pathologists, practical and philosophical considerations. A comprehensive review. *Diagn Pathol*. 2021;16(1):24.
20. Evans RS. Electronic Health Records: Then, Now, and in the Future. *Yearb Med Inform*. 2016;Suppl 1(Suppl 1):S48-S61.
21. Jiang B, Bao L, He S, Chen X, Jin Z, Ye Y. Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis. *Breast Cancer Res*. 2024;26(1):137.
22. Li F, Yang Y, Wei Y, Zhao Y, Fu J, Xiao X, et al. Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancer. *NPJ Breast Cancer*. 2022;8(1):124.
23. Shakor MY, Khaleel MI. Recent Advances in Big Medical Image Data Analysis Through Deep Learning and Cloud Computing. *Electronics*. 2024;13(24):4860.
24. Acosta JN, Falcone GJ, Rajpurkar P. Topol EJ. Multimodal biomedical AI. *Nat Med*, 2022;28;1773–84.
25. Sebastian AM, Peter D. Artificial Intelligence in Cancer Research: Trends, Challenges and Future Directions. *Life (Basel)*. 2022;12(12):1991.
26. Zhang B, Shi H, Wang H. Machine Learning and AI in Cancer Prognosis, Prediction, and Treatment Selection: A Critical Approach. *J Multidiscip Healthc*. 2023;16:1779-91.
27. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. *Nat Rev Clin Oncol*. 2019;16(11):703-15.
28. Matsuzaka Y, Yashiro R. The Diagnostic Classification of the Pathological Image Using Computer Vision. *Algorithms*. 2025;18(2):96.
29. Distante A, Marandino L, Bertolo R, Ingels A, Pavan N, Pecoraro A, et al. Artificial Intelligence in Renal Cell Carcinoma Histopathology: Current Applications and Future Perspectives. *Diagnostics (Basel).* 2023;13(13):2294.
30. Sheikhalishahi S, Miotto R, Dudley JT, Lavelli A, Rinaldi F, Osmani V. Natural Language Processing of Clinical Notes on Chronic Diseases: Systematic Review. *JMIR Med Inform*. 2019;7(2):e12239.
31. Davri A, Birbas E, Kanavos T, Ntritsos G, Giannakeas N, Tzallas AT et al. Deep Learning on Histopathological Images for Colorectal Cancer Diagnosis: A Systematic Review. *Diagnostics*. 2022;12(4):837.
32. Wang S, Pan J, Zhang X, Li Y, Liu W, Lin R, et al. Towards next-generation diagnostic pathology: AI-empowered label-free multiphoton microscopy. *Light Sci Appl*. 2024;13(1):254.
33. Proietto M, Crippa M, Damiani C, PasqualeV, Sacco E, Vanoni M et al. Tumor heterogeneity: preclinical models, emerging technologies, and future applications. *Front Oncol*. 2023;13:1164535.
34. Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtas, A et al. Artificial intelligence in cancer imaging: Clinical challenges and applications. *CA Cancer J Clin*. 2019;69(2):127-57.
35. Zadeh Shirazi A, Tofighi M, Gharavi A, Gomez GA. The Application of Artificial Intelligence to Cancer Research: A Comprehensive Guide. *Technol Cancer Res Treat*. 2024;23:15330338241250324.
36. Khalid A, Mehmood A, Alabrah A, Alkhamees BF, Amin F, AlSalman H, et al. Breast Cancer Detection and Prevention Using Machine Learning. *Diagnostics (Basel).* 2023;13(19):3113.
37. Bulten W, Balkenhol M, Belinga JA, Bonthu S, Samanta P, Singhal N, et al. Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. *Mod Pathol*. 2021;34(3):660-71.
38. Khalid U, Gurung J, Doykov M, Kostov G, Hristov B, Uchikov P et al. Artificial Intelligence Algorithms and Their Current Role in the Identification and Comparison of Gleason Patterns in Prostate Cancer Histopathology: A Comprehensive Review. *Diagnostics (Basel)*. 2024;14(19):2127.
39. Gandhi Z, Gurram P, Amgai B, Lekkala SP, Lokhandwala A, Manne S, et al. Artificial Intelligence and Lung Cancer: Impact on Improving Patient Outcomes. *Cancers (Basel)*. 2023;15(21):5236.
40. Kalidindi S. The Role of Artificial Intelligence in the Diagnosis of Melanoma. *Cureus*. 2024;16(9):e69818.
41. Shafi S, Parwani AV. Artificial intelligence in diagnostic pathology. *Diagn Pathol*. 2023;18(1):109.
42. Retamero JA, Gulturk E, Bozkurt A, Liu S, Gorgan M, Moral L, et al. Artificial Intelligence Helps Pathologists Increase Diagnostic Accuracy and Efficiency in the Detection of Breast Cancer Lymph Node Metastases. *Am J Surg Pathol*. 2024;48(7):846-54.
43. Stone P, Buckle P, Dolan R, Feliu J, Hui D, Laird BJA, et al. Prognostic evaluation in patients with advanced cancer in the last months of life: ESMO Clinical Practice Guideline. *ESMO Open*. 2023;8(2):101195.
44. Hui D. Prognostication of Survival in Patients With Advanced Cancer: Predicting the Unpredictable?. *Cancer Control*. 2015;22(4):489-97.
45. Fountzilas E, Pearce T, Baysal MA. Convergence of evolving artificial intelligence and machine learning techniques in precision oncology. *npj Digit Med*. 2025;8:75.
46. Karalis, V.D. The Integration of Artificial Intelligence into Clinical Practice. *Appl Biosci*. 2024;3(1):14-44.
47. Pinto-Coelho, L. How Artificial Intelligence Is Shaping Medical Imaging Technology: A Survey of Innovations and Applications. *Bioengineering*. 2023;10(12):1435.
48. O'Connor O, McVeigh TP. Increasing use of artificial intelligence in genomic medicine for cancer care- the promise and potential pitfalls. *BJC Rep*. 2025;3(1):20.
49. Khalighi S, Reddy K, Midya A, Pandav KB, Madabhushi A, Abedalthagafi M, et. al. Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment. *NPJ Precis Oncol*. 2024;8(1):80.
50. You Y, Lai X, Pan Y, Zheng H, Vera J, Liu S, et al. Artificial intelligence in cancer target identification and drug discovery. *Sig Transduct Target Ther*. 2022;156.
51. Pham TD, Teh MT, Chatzopoulou D, Holmes S, Coulthard P. Artificial Intelligence in Head and Neck Cancer: Innovations, Applications, and Future Directions. *Curr Oncol*. 2024;31(9):5255–90.
52. Loftus TJ, Ruppert MM, Shickel B, Ozrazgat-Baslanti T, Balch JA, Efron PA ,et al. Federated learning for preserving data privacy in collaborative healthcare research. *Digit Health*. 2022;8:20552076221134455.
53. Zarella MD, Rivera Alvarez K. High-throughput whole-slide scanning to enable large-scale data repository building. *J Pathol*. 2022;257(4):383-90.
54. Asif A, Rajpoot K, Graham S, Snead D, Minhas F, Rajpoot N. Unleashing the potential of AI for pathology: challenges and recommendations. *J Pathol*. 2023;260(5):564-77.
55. Rockenschaub P, Akay EM, Carlisle BG, Hilbert A, Wendland J, Meyer-Eschenbach F, et al. External validation of AI-based scoring systems in the ICU: a systematic review and meta-analysis. *BMC Med Inform Decis Mak*. 2025;25(1):5.
56. Seh AH, Zarour M, Alenezi M, Sarkar AK, Agrawal A, Kumar R et al. Healthcare Data Breaches: Insights and Implications. *Healthcare (Basel)*. 2020;8(2):133.
57. Chen RJ, Wang JJ, Williamson DFK, Chen TY, Lipkova J, Lu MY, et al. Algorithmic fairness in artificial intelligence for medicine and healthcare. *Nat Biomed Eng*. 2023;7(6):719–42.
58. Ferrara, E. Fairness and Bias in Artificial Intelligence: A Brief Survey of Sources, Impacts, and Mitigation Strategies. *Sci*.2024;6(1):3.
59. Palaniappan K, Lin EYT, Vogel S. Global Regulatory Frameworks for the Use of Artificial Intelligence (AI) in the Healthcare Services Sector. *Healthcare (Basel).* 2024;12(5):562.
60. Yang Y, Sun K, Gao Y, Wang K, Yu G. Preparing Data for Artificial Intelligence in Pathology with Clinical-Grade Performance. *Diagnostics (Basel)*. 2023;13(19):3115.
61. Rodriguez JPM, Rodriguez R, Silva VWK, Kitamura FC, Corradi GCA, Marchi ACB, et al. Artificial intelligence as a tool for

diagnosis in digital pathology whole slide images: A systematic review. *J Pathol Inform*. 2022;13:100138.
62. Zarella MD, McClintock DS, Batra H, et al. Artificial intelligence and digital pathology: clinical promise and deployment considerations. *J Med Imaging (Bellingham)*. 2023;10(5):051802.
63. Hazarika I. Artificial intelligence: opportunities and implications for the health workforce. *Int Health*. 2020;12(4):241–5.
64. Lynch SM, Heeran AB, Burke C, Lynam-Lennon N, Eustace AJ, Dean K, et al. Precision Oncology, Artificial Intelligence, and Novel Therapeutic Advancements in the Diagnosis, Prevention, and Treatment of Cancer: Highlights from the 59th Irish Association for Cancer Research (IACR) Annual Conference. *Cancers.* 2024;16(11):1989.
65. Kim I, Kang K, Song Y, Kim TJ. Application of Artificial Intelligence in Pathology: Trends and Challenges. *Diagnostics (Basel)*. 2022;12(11):2794.
66. Zhang Y, Weng Y, Lund J. Applications of Explainable Artificial Intelligence in Diagnosis and Surgery. *Diagnostics*. 2022;12(2):237.
67. Ye J, Woods D, Jordan N, Starren J. The role of artificial intelligence for the application of integrating electronic health records and patient-generated data in clinical decision support. *AMIA Jt Summits Transl Sci Proc*. 2024;2024:459–67.
68. Umapathy VR, Rajinikanth BS, Samuel Raj RD, Yadav S, Munavarah SA, Anandapandian PA et al. Perspective of Artificial Intelligence in Disease Diagnosis: A Review of Current and Future Endeavours in the Medical Field. *Cureus*. 2023;15(9):e45684.
69. Maleki Varnosfaderani, S.; Forouzanfar, M. The Role of AI in Hospitals and Clinics: Transforming Healthcare in the 21st Century. *Bioengineering*. 2024;11(4):337.
70. Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial Intelligence in Cancer Research and Precision Medicine. *Cancer Discov*. 2021;11(4):900015.
71. McGenity C, Clarke EL, Jennings C. Matthews G, Cartlidge C, Freduah-Agyemang H, et al. Artificial intelligence in digital pathology: a systematic review and meta-analysis of diagnostic test accuracy. *npj Digit. Med*. 2024;7(1):114
72. Ramdas KP, Khuspe K, Raut A, Chavan M, Abhang AK. Comprehensive review on digital health innovations for improving rural healthcare delivery. *J Community Health Manag*. 2025;12(1):3–13.
73. Mane D V, Khuspe P R, Machine learning in ocular oncology and oculoplasty: Transforming diagnosis and treatment. *IP Int J Ocul Oncol Oculoplasty*. 2024;10(4):196–207.

Cite this article Ramdas KP, Kale S, Mandhare T, Kashid P, Hagir D, Gaikwad V, Mane D. Emerging role of digital pathology and artificial intelligence in cancer diagnosis and prognostication. *IP J Diagn Pathol Oncol*. 2025;10(1):11-22.